Cyclooxygenase-independent neuroprotective effects of aspirin against dopamine quinone-induced neurotoxicity.
Prostaglandin H synthase exerts not only cyclooxygenase activity but also peroxidase activity. The latter activity of the enzyme is thought to couple with oxidation of dopamine to dopamine quinone. Therefore, it has been proposed that cyclooxygenase inhibitors could suppress dopamine quinone formation. In the present study, we examined effects of various cyclooxygenase inhibitors against excess methyl L-3,4-dihydroxyphenylalanine (L-DOPA)-induced quinoprotein (protein-bound quinone) formation and neurotoxicity using dopaminergic CATH.a cells. The treatment with aspirin inhibited excess methyl L-DOPA-induced quinoprotein formation and cell death. However, acetaminophen did not show protective effects, and indomethacin and meloxicam rather aggravated these methyl L-DOPA-induced changes. Aspirin and indomethacin did not affect the level of glutathione that exerts quenching dopamine quinone in dopaminergic cells. In contrast with inhibiting effects of higher dose in the previous reports, relatively lower dose of aspirin that affected methyl L-DOPA-induced quinoprotein formation and cell death failed to prevent cyclooxygenase-induced dopamine chrome generation in cell-free system. Furthermore, aspirin but not acetaminophen or meloxicam showed direct dopamine quinone-scavenging effects in dopamine-semiquinone generating systems. The present results suggest that cyclooxygenase shows little contribution to dopamine oxidation in dopaminergic cells and that protective effects of aspirin against methyl L-DOPA-induced dopamine quinone neurotoxicity are based on its cyclooxygenase-independent property.
Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. asachan@cc.okayama-u.ac.jp
Masato
M
Asanuma
Ikuko
I
Miyazaki
Yuri
Y
Kikkawa
Naotaka
N
Kimoto
Mika
M
Takeshima
Shinki
S
Murakami
Ko
K
Miyoshi
D000082:Acetaminophen / Q000494:pharmacology; D018712:Analgesics, Non-Narcotic / Q000494:pharmacology; D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D002474:Cell-Free System; D002478:Cells, Cultured; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015259:Dopamine Agents / Q000633:toxicity*; D059290:Dopaminergic Neurons / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D007980:Levodopa / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D000077239:Meloxicam; D008750:Methyldopa / Q000633:toxicity; D051379:Mice; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents; D011809:Quinones / Q000037:antagonists & inhibitors / Q000633:toxicity*; D013565:Sympatholytics / Q000633:toxicity; D013843:Thiazines / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology
D018712:Analgesics, Non-Narcotic; D016861:Cyclooxygenase Inhibitors; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D011809:Quinones; D013565:Sympatholytics; D013843:Thiazines; D013844:Thiazoles; D000082:Acetaminophen; D007980:Levodopa; D008750:Methyldopa; D005978:Glutathione; D001241:Aspirin; D000077239:Meloxicam; D007213:Indomethacin